Concepedia

David Hollenback

DH

Statistics

Publications

10

Citations

514

H-Index

10

Active since

2003

Affiliations

Gilead Sciences (United States)(Current)

David Hollenback is an author at Gilead Sciences (United States) specializing in pharmacology, life sciences, and acyltransferase enzymes.

ORCID

Publications per year

2003–2023

10

Publications

10

Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation

Jamie Bates, Archana Vijayakumar, Sarani Ghoshal et al. · Journal of Hepatology · 2020 · 225 citations · Full text

, , +17

Substrate specificity of lysophosphatidic acid acyltransferase β—evidence from membrane and whole cell assays

David Hollenback, Lynn Bonham, Laura Law et al. · Journal of Lipid Research · 2005 · 59 citations · Full text

, , +11

Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells.

Michael Coon, Alexey Ball, Jeannine Pound et al. · PubMed · 2003 · 54 citations

, , +17

Induction of Apoptosis Using Inhibitors of Lysophosphatidic Acid Acyltransferase-β and Anti-CD20 Monoclonal Antibodies for Treatment of Human Non-Hodgkin's Lymphomas

John M. Pagel, Christian Laugen, Lynn Bonham et al. · Clinical Cancer Research · 2005 · 50 citations · Full text

, , +17

Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia

Kathleen S. Keegan, Cong Li, Zhihong Li et al. · Molecular Cancer Therapeutics · 2014 · 35 citations · Full text

, , +17

1–5 of 10